Lakshmi Vineela Nalla

Dr. Lakshmi Vineela Nalla

Department of Pharmacology, GITAM Deemed to be University, Visakhapatnam, India
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 June 2023 in Diseases
Verified
Journal Article
Open access
PDF file
KRKakarla Ramakrishna
Kakarla Ramakrishna
LNLakshmi Vineela Nalla
Lakshmi Vineela Nalla
NDNaresh Dumala
Naresh Dumala
KVKojja Venkateswarlu
Kojja Venkateswarlu
MVMatte Kasi Viswanadh
Matte Kasi Viswanadh
SSSantosh Kumar Singh
Santosh Kumar Singh
Wnt/β-catenin (WβC) signaling pathway is an important signaling pathway for the maintenance of cellular homeostasis from the embryonic developmental stages to adulthood. The canonical pathway of WβC signaling is essential for neurogenesis, cell proliferation, and neurogenesis, whereas the noncanonical pathway (WNT/Ca2+ and WNT/PCP) is responsible for cell polarity, calcium maintenance, and cell migration. Abnormal regulation of WβC signaling is involved in the pathogenesis of several neurodegenerative diseases such as Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s disease (HD), amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and spinal muscular atrophy (SMA). Hence, the alteration of WβC signaling is considered a potential therapeutic target for the treatment of neurodegenerative disease. In the present review, we have used the bibliographical information from PubMed, Google Scholar, and Scopus to address the current prospects of WβC signaling role in the abovementioned neurodegenerative diseases.

6 February 2023 in Cancers
Verified
Journal Article
Open access
PDF file
Vivek P. ChavdaVivek P. Chavda
Vivek P. Chavda
LNLakshmi Vineela Nalla
Lakshmi Vineela Nalla
PBPankti Balar
Pankti Balar
RBRajashri Bezbaruah
Rajashri Bezbaruah
Vasso ApostolopoulosVasso Apostolopoulos
Vasso Apostolopoulos
Vladimir N. UverskyVladimir N. Uversky
Vladimir N. Uversky
As the world’s most prevalent cancer, breast cancer imposes a significant societal health burden and is among the leading causes of cancer death in women worldwide. Despite the notable improvements in survival in countries with early detection programs, combined with different modes of treatment to eradicate invasive disease, the current chemotherapy regimen faces significant challenges associated with chemotherapy-induced side effects and the development of drug resistance. Therefore, serious concerns regarding current chemotherapeutics are pressuring researchers to develop alternative therapeutics with better efficacy and safety. Due to their extremely biocompatible nature and efficient destruction of cancer cells via numerous mechanisms, phytochemicals have emerged as one of the attractive alternative therapies for chemotherapeutics to treat breast cancer. Additionally, phytofabricated nanocarriers, whether used alone or in conjunction with other loaded phytotherapeutics or chemotherapeutics, showed promising results in treating breast cancer. In the current review, we emphasize the anticancer activity of phytochemical-instigated nanocarriers and phytochemical-loaded nanocarriers against breast cancer both in vitro and in vivo. Since diverse mechanisms are implicated in the anticancer activity of phytochemicals, a strong emphasis is placed on the anticancer pathways underlying their action. Furthermore, we discuss the selective targeted delivery of phytofabricated nanocarriers to cancer cells and consider research gaps, recent developments, and the druggability of phytoceuticals. Combining phytochemical and chemotherapeutic agents with nanotechnology might have far-reaching impacts in the future.

27 February 2023 in ACS Pharmacology & Translational Science
Verified
Journal Article
Closed access
SCSayan Chatterjee
Sayan Chatterjee
LNLakshmi Vineela Nalla
Lakshmi Vineela Nalla
MSMonika Sharma
Monika Sharma
NSNishant Sharma
Nishant Sharma
ASAditya A. Singh
Aditya A. Singh
AKAmit Khairnar
Amit Khairnar

1 January 2020 in Neuroscience Letters
Verified
Journal Article
Closed access
APAbhijeet Parkhe
Abhijeet Parkhe
PPPathik Hiteshbhai PAREKH
Pathik Hiteshbhai PAREKH
LNLakshmi Vineela Nalla
Lakshmi Vineela Nalla
NSNishant Sharma
Nishant Sharma
MSMonika Sharma
Monika Sharma
AKAmit Khairnar
Amit Khairnar

9 March 2025 in Cells
Verified
Journal Article
Open access
PDF file
Vivek P. ChavdaVivek P. Chavda
Vivek P. Chavda
RBRajashri Bezbaruah
Rajashri Bezbaruah
NANasima Ahmed
Nasima Ahmed
SAShahnaz Alom
Shahnaz Alom
BBBedanta Bhattacharjee
Bedanta Bhattacharjee
Vasso ApostolopoulosVasso Apostolopoulos
Vasso Apostolopoulos
Pulmonary homeostasis can be agitated either by external environmental insults or endogenous factors produced during respiratory/pulmonary diseases. The lungs counter these insults by initiating mechanisms of inflammation as a localized, non-specific first-line defense response. Cytokines are small signaling glycoprotein molecules that control the immune response. They are formed by numerous categories of cell types and induce the movement, growth, differentiation, and death of cells. During respiratory diseases, multiple proinflammatory cytokines play a crucial role in orchestrating chronic inflammation and structural changes in the respiratory tract by recruiting inflammatory cells and maintaining the release of growth factors to maintain inflammation. The issue aggravates when the inflammatory response is exaggerated and/or cytokine production becomes dysregulated. In such instances, unresolving and chronic inflammatory reactions and cytokine production accelerate airway remodeling and maladaptive outcomes. Pro-inflammatory cytokines generate these deleterious consequences through interactions with receptors, which in turn initiate a signal in the cell, triggering a response. The cytokine profile and inflammatory cascade seen in different pulmonary diseases vary and have become fundamental targets for advancement in new therapeutic strategies for lung diseases. There are considerable therapeutic approaches that target cytokine-mediated inflammation in pulmonary diseases; however, blocking specific cytokines may not contribute to clinical benefit. Alternatively, broad-spectrum anti-inflammatory approaches are more likely to be clinically effective. Herein, this comprehensive review of the literature identifies various cytokines (e.g., interleukins, chemokines, and growth factors) involved in pulmonary inflammation and the pathogenesis of respiratory diseases (e.g., asthma, chronic obstructive pulmonary, lung cancer, pneumonia, and pulmonary fibrosis) and investigates targeted therapeutic treatment approaches.

1 February 2019 in The International Journal of Biochemistry & Cell Biology
Verified
Journal Article
Closed access
LNLakshmi Vineela Nalla
Lakshmi Vineela Nalla
KKKiran Kalia
Kiran Kalia
AKAmit Khairnar
Amit Khairnar